Tweet
Nat Commun
. 2024 Feb 19;15(1):1492.
doi: 10.1038/s41467-024-45468-9. Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study
John S Kim 1 2 , Yifei Sun 3 , Pallavi Balte 2 , Mary Cushman 4 5 , Rebekah Boyle 5 , Russell P Tracy 5 , Linda M Styer 6 , Taison D Bell 1 , Michaela R Anderson 7 , Norrina B Allen 8 , Pamela J Schreiner 9 , Russell P Bowler 10 , David A Schwartz 11 , Joyce S Lee 11 , Vanessa Xanthakis 12 13 , Margaret F Doyle 5 , Elizabeth A Regan 14 , Barry J Make 10 , Alka M Kanaya 15 , Sally E Wenzel 16 , Josef Coresh 17 18 , Carmen R Isasi 19 , Laura M Raffield 20 , Mitchell S V Elkind 21 22 , Virginia J Howard 23 , Victor E Ortega 24 , Prescott Woodruff 25 , Shelley A Cole 26 , Joel M Henderson 27 , Nicholas J Mantis 6 28 , Monica M Parker 6 , Ryan T Demmer # 29 30 31 , Elizabeth C Oelsner # 32
Affiliations
This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.
. 2024 Feb 19;15(1):1492.
doi: 10.1038/s41467-024-45468-9. Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study
John S Kim 1 2 , Yifei Sun 3 , Pallavi Balte 2 , Mary Cushman 4 5 , Rebekah Boyle 5 , Russell P Tracy 5 , Linda M Styer 6 , Taison D Bell 1 , Michaela R Anderson 7 , Norrina B Allen 8 , Pamela J Schreiner 9 , Russell P Bowler 10 , David A Schwartz 11 , Joyce S Lee 11 , Vanessa Xanthakis 12 13 , Margaret F Doyle 5 , Elizabeth A Regan 14 , Barry J Make 10 , Alka M Kanaya 15 , Sally E Wenzel 16 , Josef Coresh 17 18 , Carmen R Isasi 19 , Laura M Raffield 20 , Mitchell S V Elkind 21 22 , Virginia J Howard 23 , Victor E Ortega 24 , Prescott Woodruff 25 , Shelley A Cole 26 , Joel M Henderson 27 , Nicholas J Mantis 6 28 , Monica M Parker 6 , Ryan T Demmer # 29 30 31 , Elizabeth C Oelsner # 32
Affiliations
- PMID: 38374032
- PMCID: PMC10876680
- DOI: 10.1038/s41467-024-45468-9
This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.